Cocrystal Pharma, Inc. (COCP)
1.135
+0.02
(+2.25%)
USD |
NASDAQ |
Aug 25, 16:00
1.135
0.00 (0.00%)
After-Hours: 19:59
Cocrystal Pharma Enterprise Value : 14.40M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 14.40M |
| August 21, 2026 | 14.95M |
| August 20, 2026 | 15.23M |
| August 19, 2026 | 14.89M |
| August 18, 2026 | 13.99M |
| August 17, 2026 | 14.13M |
| August 14, 2026 | 14.54M |
| August 13, 2026 | 14.26M |
| August 12, 2026 | 14.54M |
| August 11, 2026 | 13.99M |
| August 10, 2026 | 13.99M |
| August 07, 2026 | 13.71M |
| August 06, 2026 | 13.30M |
| August 05, 2026 | 13.16M |
| August 04, 2026 | 12.61M |
| August 03, 2026 | 12.06M |
| July 31, 2026 | 10.40M |
| July 30, 2026 | 11.06M |
| July 29, 2026 | 11.10M |
| July 28, 2026 | 11.99M |
| July 27, 2026 | 11.76M |
| July 24, 2026 | 11.51M |
| July 23, 2026 | 11.78M |
| July 22, 2026 | 12.01M |
| July 21, 2026 | 11.92M |
| Date | Value |
|---|---|
| July 20, 2026 | 11.92M |
| July 17, 2026 | 12.20M |
| July 16, 2026 | 12.20M |
| July 15, 2026 | 12.33M |
| July 14, 2026 | 12.06M |
| July 13, 2026 | 12.33M |
| July 10, 2026 | 13.02M |
| July 09, 2026 | 13.02M |
| July 08, 2026 | 12.64M |
| July 07, 2026 | 13.16M |
| July 06, 2026 | 13.44M |
| July 02, 2026 | 13.44M |
| July 01, 2026 | 13.58M |
| June 30, 2026 | 13.58M |
| June 29, 2026 | 10.86M |
| June 26, 2026 | 10.73M |
| June 25, 2026 | 10.59M |
| June 24, 2026 | 11.14M |
| June 23, 2026 | 11.28M |
| June 22, 2026 | 10.45M |
| June 18, 2026 | 10.38M |
| June 17, 2026 | 10.06M |
| June 16, 2026 | 9.709M |
| June 15, 2026 | 10.31M |
| June 12, 2026 | 10.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| CNBX Pharmaceuticals, Inc. | 1.379M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 50.20M |
| Fulcrum Therapeutics, Inc. | -20.63M |
| Definium Therapeutics, Inc. | 4.767B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.164M |
| Revenue (Quarterly) | 0.105M |
| Total Expenses (Quarterly) | 3.269M |
| EPS Diluted (Quarterly) | -0.2295 |
| Gross Profit Margin (Quarterly) | 88.57% |
| Profit Margin (Quarterly) | -3.01K% |
| Earnings Yield | -66.85% |
| Normalized Earnings Yield | -66.85 |